Gavi-supported immunisation generated more than US$ 30 billion in economic benefits in 2025, through lower healthcare costs and healthier, more productive populations Recognising the value of immunisation, countries invested a record US$ 301 million in co-financing of Gavi-supported vaccines in 2025 Dr Sania Nishtar, Gavi CEO: “When it comes to immunisation we know that the…
Next-generation TB vaccines, expected to become available from 2029, could deliver major health and economic gains, helping to save an estimated 7.3 million lives, generate up to US$ 135 billion in economic benefits for low-and middle-income countries by 2050, and support efforts to combat antimicrobial resistance. Action must be taken now to ensure that countries…
Gavi said an estimated 10.7 million people developed TB and 1.2 million died from the disease globally in 2024. New tuberculosis (TB) vaccines expected to become available from 2029 could save up to 7.3 million lives globally between 2030 and 2050, Gavi, the Vaccine Alliance, has said. This was contained in a statement issued by…
Geneva/New York/Copenhagen — A global initiative to establish a stockpile of mpox vaccines was launched on 27 August, creating a long-term mechanism to ensure countries have access to vaccines when responding to mpox outbreaks. Set to begin operations later this month, this new global mpox vaccine stockpile that all countries can access is a resource…
President Donald Trump has signed an order that calls for fewer childhood vaccines and also recommends splitting the mumps, measles and rubella (MMR) shots. “Decades ago, children received only a small fraction of the vaccines required today,” Trump said on Monday. “In those times, people were much healthier and of course the high rates of…
Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process. Traditionally, researchers had to tailor manufacturing processes and facilities for each vaccine candidate, and the scientific knowledge gained from one vaccine was often not directly transferable to another….
In response to the current outbreak of Ebola disease caused by Bundibugyo virus occurring in the Democratic Republic of the Congo, with cases also reported in Uganda, WHO convened several of its expert and advisory groups. These groups assessed potential vaccines and therapeutics for both prevention and treatment of Bundibugyo virus disease (BVD). The WHO…
Dengue, a mosquito-borne disease, affects millions of people every year across Asia, Africa and Latin America. And it’s expanding geographically as warmer temperatures and urban growth allow mosquito populations to thrive in new regions. At first glance, dengue seems like an obvious candidate for vaccination. It is caused by a virus. Infection triggers an immune…
We are now approaching six years since COVID-19 was declared a pandemic by the World Health Organization, yet talk of vaccines and our immune systems persists in our cultural conversations — from political arenas to the dinner table. The vaccination conversation has extended beyond the scientific community, resulting in controversial changes to the recommended vaccination…
The roadmap was developed under the leadership of the West African Health Organisation (WAHO), with support from the Coalition for Epidemic Preparedness Innovations (CEPI), as part of efforts to strengthen epidemic preparedness and vaccine equity across the sub-region. West African countries have launched a regional framework aimed at ensuring equitable access to Lassa fever vaccines…
